Gait as a quantitative translational outcome measure in Angelman syndrome.

This is an animal study using mice, so findings cannot be directly applied to human patients without further clinical validation. The study did not test multiple treadmill speeds, so it is unclear if the observed gait patterns (like reduced double support) are a compensatory strategy for a fixed speed or a true deficit. The authors note that detailed temporal gait metrics have not been commonly reported in other neurodevelopmental disorder models, limiting comparison. The study focused on motor outcomes only; it did not assess communication, cognition, or social behaviors, so the link between gait and other domains remains theoretical.

Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Neurological Disorders and Stroke, the Intellectual and Developmental Disabilities Research Center, and the Foundation for Angelman Syndrome Therapeutics.

Do not interpret these gait findings as evidence that a specific therapy works. This study describes the natural progression of motor deficits in mice to establish baseline metrics for future trials; it did not test any treatment.